Exeliom
ID: 7369509Exeliom is a developer of microbiome-based immunotherapies founded in 2016 by Benjamin Hadida, Harry Sokol, Patrick Gervais and Philippe Langella.
2
Funding Rounds
$11.6m
Money raised
Recent Funding Rounds
Overview
Exeliom is a developer of microbiome-based immunotherapies founded in 2016 by Benjamin Hadida, Harry Sokol, Patrick Gervais and Philippe Langella.
- Website:
- Business model: B2B
- Headquarters: Paris
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
| Name | Phone | Social networks | |
|---|---|---|---|
| Be****** Ha**** |
|
- | |
| Ha*** So*** |
|
- | |
| Pa***** Ge***** | - | - | - |
| Ph****** La****** |
|
- |
Funding series
Funding Series Analysis
The company Exeliom has raised a total of $3.3m in funding over 2 rounds.
Key Insights:
- Exeliom Series A Round, October 2025: $3.3m
- Exeliom Series A round, July 2018: $8.33m
Industries
Exeliom is active in the following industries: